Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brown, B. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brown, B. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Niaspan® in the management of dyslipidaemia: the evidence

B. Greg Brown

Division of Cardiology, University of Washington, A-509 Health Sciences Center, Seattle, WA 98195-6422, USA

Corresponding author. Tel: +1 425 454 6403; fax: +1 206 616 4302. E-mail address: bgbrown{at}u.washington.edu

Simultaneous correction of hyperlipidaemia and low HDL-cholesterol may provide superior cardiovascular protection than a single pharmacological lipid-modifying strategy. Combinations of nicotinic acid (the most effective HDL-raising agent currently available) and a statin have been especially well studied. The HDL Atherosclerosis Treatment Study (HATS) demonstrated regression of atherosclerosis and a 60–90% reduction in cardiovascular event rates in patients with cardiovascular disease and low HDL-cholesterol who were randomized to receive a combination of immediate-release nicotinic acid and a statin when compared with patients randomized to placebo. Niaspan®, a prolonged-release formulation of nicotinic acid with superior tolerability to the immediate-release version also reduced the progression of atherosclerosis, in the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2) study, although this trial was not powered to evaluate outcomes. The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL-C/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study will test the hypothesis that treatment with Niaspan® plus a statin will provide superior cardiovascular outcomes to a statin given alone in a population of >3000 patients with vascular disease and atherogenic dyslipidaemia (low HDL-cholesterol and hypertriglyceridaemia). The results of AIM-HIGH will be available in 2010. However, the current clinical evidence base supports intensive intervention to correct low HDL-cholesterol today.

Key Words: HDL-cholesterol • Nicotinic acid • Niacin • HMG-CoA reductase inhibitors • Statins • Cardiovascular events


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.